Search

Your search keyword '"Rolland F"' showing total 551 results
Start Over Author "Rolland F"
551 results on '"Rolland F"'

1. Beneath HMGA2 alterations in pleomorphic adenomas: Pathological, immunohistochemical, and molecular insights

Author

Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Grayeli, A.Bozorg, Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F.R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Saint Guily, J. Lacau, Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Cardon, A.Lasne, Le Tourneau, C., Lefebvre, G., Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A., Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Dang, N. Pham, Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., J.-M.Prades, Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Siegfried, A., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., J.Thariat, David, M. Timar, Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., Wong, S., Alsugair, Ziyad, Lépine, Charles, Descotes, Françoise, Lanic, Marie-Delphine, Pissaloux, Daniel, Tirode, Franck, Lopez, Jonathan, Céruse, Philippe, Philouze, Pierre, Fieux, Maxime, Wassef, Michel, Baglin, Anne-Catherine, Mihaela, Onea, Castain, Claire, Sudaka, Anne, Uro-Coste, Emmanuelle, Champagnac, Anne, Costes-Martineau, Valérie, Laé, Marick, and Benzerdjeb, Nazim

Published
2024
Full Text
View/download PDF

2. Characterization of a Molecularly Distinct Subset of Oncocytic Pleomorphic Adenomas/Myoepitheliomas Harboring Recurrent ZBTB47-AS1: PLAG1 Gene Fusion

Author

Alsugair, Ziyad, Perrot, Jimmy, Descotes, Françoise, Lopez, Jonathan, Champagnac, Anne, Pissaloux, Daniel, Castain, Claire, Onea, Mihaela, Céruse, Philippe, Philouze, Pierre, Lépine, Charles, Lanic, Marie-Delphine, Laé, Marick, Costes-Martineau, Valérie, Benzerdjeb, Nazim, Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Grayeli, A. Bozorg, Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F. R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Saint Guily, J. Lacau, Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Cardon, A. Lasne, Le Tourneau, C., Lefebvre, G, Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A, Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Dang, N. Pham, Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., David, M. Timar, Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., and Wong, S.

Published
2024
Full Text
View/download PDF

3. Impact of facial nerve resection in parotid cancer abutting the facial nerve without preoperative paralysis: A multicentric propensity score-based analysis

Author

Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Bettoni, J., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Bozorg Grayeli, A., Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Classe, M., Clatot, F., Colin, E., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Espitalier, F., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F.R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Lacau Saint Guily, J., Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Lasne Cardon, A., Le Tourneau, C., Lefebvre, G., Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A., Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Pham Dang, N., Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., Timar David, M., Timochenko, A., Toussaint, B., Uro Coste, E., Valette, G., Van den Abbeele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., Wong, S., Chatelet, Florian, Chevret, Sylvie, Fakhry, Nicolas, Even, Caroline, Malard, Olivier, de Monès, Erwan, Saroul, Nicolas, Mouawad, François, de Boutray, Marie, Mauvais, Olivier, Vergez, Sébastien, Evrard, Diane, Righini, Christian, Schultz, Philippe, Baudouin, Robin, Poissonnet, Gilles, Atallah, Sarah, Haroun, Fabienne, Morinière, Sylvain, Evrard, Camille, Philouze, Pierre, Paasche, Agnès, Lesnik, Maria, Lelonge, Yann, Herman, Philippe, and Verillaud, Benjamin

Published
2024
Full Text
View/download PDF

4. Basal/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial

Author

Pignot, G., Fendler, J.P., Guy, L., Verhoest, G., Mottet, N., Doerfler, A., Abadie-Lacourtoisie, S., Azzouzi, A., Mongiat, P., Geoffrois, L., Eschwege, P., Di Fiore, F., Roubaud, G., Hoepffner, J.L., Barthelemy, P., Lang, H., Voog, E., Mandron, E., Tourani, J.M., Serrrate, C., Colau, A., Saldana, C., de La Taille, A., Nguyen, T., Kleinclauss, F., Loriot, Y., Irani, J., Eymard, J.C., Larre, S., Huillard, O., Zerbib, M., Rolland, F., Rigaud, J., Houede, N., Droupy, S., Malouf, G., Roupret, M., Vieillot, S., Letang, N., Lharidon, T., Gaschignard, N., Hilgers, W., Davin, J.L., Groeneveld, C.S., Pfister, C., Culine, S., Harter, V., Krucker, C., Fontugne, J., Dixon, V., Sirab, N., Bernard-Pierrot, I., de Reyniès, A., Radvanyi, F., and Allory, Y.

Published
2024
Full Text
View/download PDF

5. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases

Author

Albert, S., Andry, G., Babin, E., Bach, C., Badet, J.-M., Badoual, C., Baglin, A.C., Banal, A., Barry, B., Baudin, E., Baujat, B., Bensadoun, R.J., Bertolus, C., Bessède, J.-P., Blanchard, D., Borel, C., Bozorg-Grayeli, A., Breheret, R., Breton, P., Brugel, L., Calais, G., Casiraghi, O., Cassagnau, E., Castillo, L., Ceruse, P., Chabolle, F., Chevalier, D., Chobaut, J.C., Choussy, O., Cosmidis, A., Coste, A., Costes, V., Crampette, L., Darrouzet, V., Demez, P., Dessi, P., Devauchelle, B., Dolivet, G., Dubrulle, F., Duflo, S., Dufour, X., Faivre, S., Fakhry, N., Ferron, C., Floret, F., de Gabory, L., Garrel, R., Geoffrois, L., Gilain, L., Giovanni, A., Girod, A., Guerrier, B., Hans, S., Herman, P., Hofman, P., Housset, M., Jankowski, R., Jegoux, F., Juliéron, M., Kaminsky, M.-C., Kolb, F., St Guily, J. Lacau, Laccoureye, L., Lallemant, B., Lang, P., Lartigau, E., Lavieille, J.-P., Lefevre, M., Leroy, X., Malard, O., Massip, F., Mauvais, O., Merol, J.-C., Michel, J., Mom, T., Morinière, S., de Monès, E., Moulin, G., Noel, G., Poissonnet, G., Prades, J.-M., Radulesco, T., de Raucourt, D., Reyt, E., Righini, C., Robin, Y. Marie, Rolland, F., Ruhin, B., Sarroul, N., Schultz, P., Serrano, E., Sterkers, O., Strunski, V., Sudaka, A., Tassart, M., Testelin, S., Thariat, J., Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbeele, T., Varoquaux, A., Veillon, F., Vergez, S., Wassef, M., Dahan, Laurie Saloner, Giorgi, Roch, Vergez, Sébastien, Le Taillandier de Gabory, Ludovic, Costes-Martineau, Valérie, Herman, Philippe, Poissonnet, Gilles, Mauvais, Olivier, Malard, Olivier, Garrel, Renaud, Uro-Coste, Emmanuelle, Barry, Béatrix, Bach, Christine, Chevalier, Dominique, Mouawad, Francois, Merol, Jean-Claude, Bastit, Vianney, Thariat, Juliette, Gilain, Laurent, Dufour, Xavier, Righini, Christian-Adrien, Moya-Plana, Antoine, Even, Caroline, Radulesco, Thomas, Michel, Justin, Baujat, Bertrand, and Fakhry, Nicolas

Published
2021
Full Text
View/download PDF

6. Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study

Author

Grünwald, V., primary, Powles, T., additional, Kopyltsov, E., additional, Kozlov, V., additional, Alonso-Gordoa, T., additional, Eto, M., additional, Hutson, T., additional, Motzer, R., additional, Winquist, E., additional, Maroto, P., additional, Keam, B., additional, Procopio, G., additional, Wong, S., additional, Melichar, B., additional, Rolland, F., additional, Oya, M., additional, Rodriguez-Lopez, K., additional, Saito, K., additional, McKenzie, J., additional, and Porta, C., additional

Published
2024
Full Text
View/download PDF

7. Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases

Author

Loriot, Y., Pagliaro, L., Fléchon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., Chevreau, C., Delva, R., Rolland, F., Theodore, C., Roubaud, G., Gravis, G., Eymard, J.C., Malhaire, J.P., Linassier, C., Habibian, M., Martin, A.L., Journeau, F., Reckova, M., Logothetis, C., Laplanche, A., Le Teuff, G., Culine, S., and Fizazi, K.

Published
2017
Full Text
View/download PDF

8. Characterization of a Molecularly Distinct Subset of Oncocytic Pleomorphic Adenomas/Myoepitheliomas Harboring Recurrent ZBTB47-AS1::PLAG1Gene Fusion

Author

Alsugair, Ziyad, Perrot, Jimmy, Descotes, Françoise, Lopez, Jonathan, Champagnac, Anne, Pissaloux, Daniel, Castain, Claire, Onea, Mihaela, Céruse, Philippe, Philouze, Pierre, Lépine, Charles, Lanic, Marie-Delphine, Laé, Marick, Costes-Martineau, Valérie, Benzerdjeb, Nazim, Ala-Eddine, C., Aubry, K., Babin, E., Bach, C., Badoual, C., Baglin, A.C., Barry, B., Bastit, V., Baujat, B., Benezery, K., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bertolus, C., Biet, A., Bodmer, D., Boisselier, P., Boulagnon-Rombi, C., Bozec, L., Grayeli, A. Bozorg, Brenet, E., Brugel, L., Calais, G., Calugaru, V., Camby, S., Casiraghi, O., Cassagnau, E., Castain, C., Castelli, J., Ceruse, P., Chabolle, F., Chevalier, D., Choussy, O., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Coutte, A., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Devauchelle, B., Digue, L., Dolivet, G., Doré, M., Duflo, S., Dufour, X., Dupin, C., Eker, E., Even, C., Evrard, C., Fabiano, E., Faivre, S., Fakhry, N., Ferrand, F. R., Frandon, J., Franetti, D., de Gabory, L., Galy, C., Garcier, M., Garrel, R., Gauthier, H., Gilain, L., Guihard, S., Guillerm, S., Halimi, C., Hans, S., Herman, P., Houessinon, A., Hourseau, M., Huguet, F., Jadaud, E., Jankowski, R., Jeanne, C., Jegoux, F., Juliéron, M., Kaci, R., Kaminsky, M.-C., de Kermadec, H., Kolb, F., Kreps, S., Laadhari, M., Saint Guily, J. Lacau, Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lallemant, B., Lamuraglia, M., Lang, P., Lapeyre, M., Lapierre, A., Cardon, A. Lasne, Le Tourneau, C., Lefebvre, G, Lefevre, M., Lelonge, Y., Leroy, X., Lesnik, M., Liem, X., Linassier, C., Maingon, P., Majoufre, C., Malard, O., Malouf, G., Marchand, C., Marie, J.-P., Maurina, T., Mauvais, O., Merol, J.-C., Michel, J., Mineur, G., Mirafzal, S., Mirghani, H., Modesto, A., Molinier-Blossier, S., de Monès, E., Morinière, S., Mouawad, F., Moya-Plana, A, Muller, L., Musat, E., Nguyen, F., Noel, G., Obongo-Anga, F.R., Onea, M., Orliac, H., Page, C., Patron, V., Pestre, J., Dang, N. Pham, Philouze, P., Poissonnet, G., Pons, C., Pouliquen, C., Prades, J.-M., Prevost, A., Queiros, C., Rahmani, A., Rambeau, A., Ramin, L., Renard, S., Righini, C.A., Rolland, F., Saada, E., Sacino, F., Salas, S., Saroul, N., Schultz, P., Simonaggio, A., Sterkers, O., Strunski, V., Sudaka, A., Xu-Shan, S., Taouachi, R., Tassart, M., Testelin, S., Thariat, J., David, M. Timar, Timochenko, A., Toussaint, B., Coste, E. Uro, Valette, G., Van den Abbele, T., Varoquaux, A., Vauleon, E., Vergez, S., Verillaud, B., Villa, J., Villepelet, A., Volondat, M., Vulquin, N., Wagner, I., Wassef, M., Webert, L., and Wong, S.

Abstract

Recurrent gene fusions are common in salivary gland tumors including benign tumors, such as pleomorphic adenoma (PA) and myoepithelioma (ME). In cases where chromosomal rearrangement is identified in the pleomorphic adenoma gene 1 (PLAG1)gene, different gene partners are found. Oncocytic metaplasia, characterized by oncocytes with abundant eosinophilic granular cytoplasm and hyperchromatic nuclei, is a well-known phenomenon in salivary gland neoplasms. However, the pure oncocytic variant of PA/ME showed PLAG1gene rearrangements involving various gene partners at the molecular level, without any recurrent fusion being found. Our study includes 20 cases of PA/ME, with 11 females and 9 males. The age of patients ranged from 37 to 96 years, with a median age of 62.8 years. Most tumors originate from the parotid gland. The median size of the tumor was 26.5 mm (range: 13 to 60 mm). Among the 20 cases, 14 were a pure oncocytic variant of PA/ME, whereas 6 cases showed focal oncocytic or oncocytic-like aspects. Molecular studies on 20 cases of PA/ME were conducted. A novel recurrent ZBTB47-AS1::PLAG1fusion was identified in 6 of 12 cases with pure oncocytic metaplasia, whereas the other cases had PLAG1gene fusion with different gene partners. The transcriptomic analysis of the cases harboring ZBTB47-AS1::PLAG1fusion demonstrated that these tumors have a distinct molecular profile from conventional PA/ME. This study reveals a unique subset in the oncocytic PA/ME spectrum characterized by pure oncocytic morphology with larger oncocytic cells and recurrent ZBTB47-AS1::PLAG1fusion. It also highlights the transcriptomic distinctness of salivary gland adenomas with pure oncocytic metaplasia in the spectrum of salivary gland neoplasms. Further studies are needed to better understand the oncocytic variant of PA/ME and to determine the true nature of oncocytic cells in PA/ME.

Published
2024
Full Text
View/download PDF

13. Impact of subsequent therapies in patients (pts) with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab (LEN+PEMBRO) or sunitinib (SUN) in the CLEAR study

Author

Voss, M.H., primary, Powles, T., additional, Mcgregor, B., additional, Porta, C., additional, Grünwald, V., additional, Merchan, J.R., additional, Rolland, F., additional, Maroto-Rey, P., additional, Goh, J.C., additional, Xing, D., additional, Perini, R.F., additional, Mckenzie, J., additional, Mody, K., additional, and Motzer, R.J., additional

Published
2022
Full Text
View/download PDF

16. 854MO Avelumab-cetuximab-radiotherapy (RT) versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Final analysis of randomized phase III GORTEC 2017-01 REACH trial

Author

Tao, Y., Auperin, A., Sun, X., Liem, X., Sire, C., Martin, L., Pointreau, Y., Borel, C., Kaminsky-Forrett, M-C., Miroir, J., Rolland, F., Coutte, A., Clatot, F., Sinigaglia, L., Thariat, J., Even, C., Saada, E.B., Guigay, J., and Bourhis, J.

Published
2024
Full Text
View/download PDF

17. Pengaruh Ganda Terhadap Kinerja Tenaga Medis Wanita Melalui Stres Kerja

Author

Maria Laurensia Yusifina Dengi Dando, Rolland F. Fanggidae, and Apriana H J Fanggidae

Abstract

Tujuan Penelitian ini adalah untuk mengetahui apakah Peran Ganda dan Stres Kerja berpengaruh secara parsial terhadap Kinerja tenaga medis wanita, apakah Peran Ganda dan Stres Kerja secara simultan berpengaruh terhadap Kinerja tenaga medis wanita dan apakah Peran Ganda Berpengaruh terhadap Kinerja tenaga medis wanita melalui Stres Kerja di Puskesmas Baun Kabupaten Kupang. Metode yang digunakan dalam adalah pendekatan kuantitatif asosiatif. Penelitian ini di laksanakan pada Puskesmas Baun Kabupaten Kupang dengan jumlah sampel 38 orang dengan mengunakan total sampling, dan untuk mengumpulkan data di lapangan menggunakan kuesioner. Teknik analisis yang digunakan dalam penelitian ini adalah analisis regresis linier berganda dan uji sobel. Hasil Penelitian menemukan bahwa secara parsial peran ganda berpengaruh terhadap stres kerja tenaga medis wanita, sedangkan stres kerja tidak berpengaruh terhadap kinerja tenaga medis wanita. Sementara itu secara simultan peran ganda dan stress kerja berpengaruh terhadap kinerja tenaga medis wanita dan Stres Kerja tidak dapat memediasi pengaruh Peran Ganda terhadap Kinerja tenaga medis melalui Stres Kerja sebagai variable intervening. Kata kunci : Peran Ganda, Stress Kerja, Kinerja, Intervening, Puskesmas Baun Kabupaten Kupang

Published
2021

20. Impact of the first wave of the COVID-19 pandemic on French Health students

Author

Rolland, F., Frajerman, A., Falissard, B., Bertschy, G., Diquet, B., and Marra, D.

Abstract

In France, care workers and health students have been intensely mobilized during the first wave of the COVID-19 pandemic. But few studies have evaluated psychological distress on non-medical health students, in addition to the challenges posed by pedagogical continuity while universities are closed following health and safety regulations.

Published
2023
Full Text
View/download PDF

23. Profil clinique et qualité de vie des patients asthmatiques sévères de phénotype T2 traités par biothérapies en France : résultats en vraie vie de l’étude multicentrique « Second Souffle »

Author

Didier, A., primary, Raherison-Semjen, C., additional, Camus, C., additional, Verdier, E., additional, Bourdin, A., additional, Bonniaud, P., additional, Fry, S., additional, Devouassoux, G., additional, Blanc, F.X., additional, Pison, C., additional, Dupin, C., additional, Khayath, N., additional, Courdeau, J., additional, Valcke-Brossollet, J., additional, Nocent-Ejnaini, C., additional, Rolland, F., additional, Iamandi, C., additional, Proust, A., additional, Ozier, A., additional, Portel, L., additional, Gaspard, W., additional, Roux-Claude, P., additional, Beurnier, A., additional, Martinez, S., additional, Dot, J.M., additional, Hennegrave, F., additional, Vignal, G., additional, Auvray, E., additional, Paleiron, N., additional, Just, N., additional, Miltgen, J., additional, Russier, M., additional, Olivier, C., additional, Guilleminault, L., additional, and Taillé, C., additional

Published
2022
Full Text
View/download PDF

24. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†

Author

Kramar, A., Negrier, S., Sylvester, R., Joniau, S., Mulders, P., Powles, T., Bex, A., Bonnetain, F., Bossi, A., Bracarda, S., Bukowski, R., Catto, J., Choueiri, T. K., Crabb, S., Eisen, T., El Demery, M., Fitzpatrick, J., Flamand, V., Goebell, P. J., Gravis, G., Houédé, N., Jacqmin, D., Kaplan, R., Malavaud, B., Massard, C., Melichar, B., Mourey, L., Nathan, P., Pasquier, D., Porta, C., Pouessel, D., Quinn, D., Ravaud, A., Rolland, F., Schmidinger, M., Tombal, B., Tosi, D., Vauleon, E., Volpe, A., Wolter, P., Escudier, B., Filleron, T., Kramar, Andrew, Sylvester, Richard, Filleron, Thomas, Negrier, Sylvie, Joniau, Steven, Mulders, Peter, Powles, Thomas, Escudier, Bernard, Bex, Axel, Bonnetain, Franck, Bossi, Alberto, Braccarda, Sergio, Bukowski, Ronald, Catto, James, Choueiri, Toni, Crabb, Simon, Eisen, Tim, El Demery, Mounira, Fitzpatrick, John, Flamand, Vincent, Goebell, Peter J., Gravis, Gwendael, Houédé, Nadine, Jacqmin, Didier, Kaplan, Richard, Malavaud, Bernard, Massard, Christophe, Melichar, Bohuslav, Mourey, Loïc, Nathan, Paul, Pasquier, David, Porta, Camillo, Pouessel, Damien, Quinn, David, Ravaud, Alain, Rolland, Frédéric, Schmidinger, Manuela, Tombal, Bertrand, Tosi, Diego, Vauleon, Elodie, Volpe, Alessandro, and Wolter, Pascal

Published
2015
Full Text
View/download PDF

25. 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)

Author

Alves Costa Silva, C., primary, Derosa, L., additional, Dalban, C., additional, Colomba, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis, G., additional, Oudard, S.M., additional, Laguerre, B., additional, Barthelemy, P., additional, Borchiellini, D., additional, Gross-Goupil, M., additional, Geoffrois, L., additional, Rolland, F., additional, Thiery-Vuillemin, A., additional, Joly, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

26. 657MO Antibiotic (ATB) therapy and outcome from nivolumab (N) in metastatic renal cell carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN multicentric phase II study

Author

Derosa, L., primary, Alves Costa Silva, C., additional, Dalban, C., additional, Colomba, E., additional, Negrier, S., additional, Chevreau, C.M., additional, Gravis, G., additional, Oudard, S.M., additional, Laguerre, B., additional, Barthelemy, P., additional, Borchiellini, D., additional, Gross-Goupil, M., additional, Geoffrois, L., additional, Rolland, F., additional, Thiery-Vuillemin, A., additional, Joly, F., additional, Ladoire, S., additional, Tantot, F., additional, Escudier, B., additional, and Albiges, L., additional

Published
2021
Full Text
View/download PDF

27. 713P Assessment of bleomycin pulmonary toxicity in men with poor-prognosis non-seminomatous germ-cell tumors treated in the GETUG 13 phase III trial

Author

Naoun, N., primary, Le Teuff, G., additional, Pagliaro, L., additional, Fléchon, A., additional, Mardiak, J., additional, Geoffrois, L., additional, Kerbrat, P., additional, Chevreau, C.M., additional, Delva, R., additional, Rolland, F., additional, Theodore, C., additional, Roubaud, G., additional, Gravis, G., additional, Eymard, J-C., additional, Malhaire, J.P., additional, Linassier, C., additional, Reckova, M., additional, Nenan, S., additional, Culine, S., additional, and Fizazi, K., additional

Published
2021
Full Text
View/download PDF

29. LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

Author

Bourhis, J., primary, Tao, Y., additional, Sun, X., additional, Sire, C., additional, Martin, L., additional, Liem, X., additional, Coutte, A., additional, Pointreau, Y., additional, Thariat, J., additional, Miroir, J., additional, Rolland, F., additional, Kaminsky, M-C., additional, Borel, C., additional, Maillard, A., additional, Sinigaglia, L., additional, Guigay, J., additional, Saada-Bouzid, E., additional, Even, C., additional, and Aupérin, A., additional

Published
2021
Full Text
View/download PDF

31. Mucoepidermoid carcinoma of salivary glands: A French Network of Rare Head and Neck Tumors (REFCOR) prospective study of 292 cases

Author

Dahan, Laurie Saloner, primary, Giorgi, Roch, additional, Vergez, Sébastien, additional, Le Taillandier de Gabory, Ludovic, additional, Costes-Martineau, Valérie, additional, Herman, Philippe, additional, Poissonnet, Gilles, additional, Mauvais, Olivier, additional, Malard, Olivier, additional, Garrel, Renaud, additional, Uro-Coste, Emmanuelle, additional, Barry, Béatrix, additional, Bach, Christine, additional, Chevalier, Dominique, additional, Mouawad, Francois, additional, Merol, Jean-Claude, additional, Bastit, Vianney, additional, Thariat, Juliette, additional, Gilain, Laurent, additional, Dufour, Xavier, additional, Righini, Christian-Adrien, additional, Moya-Plana, Antoine, additional, Even, Caroline, additional, Radulesco, Thomas, additional, Michel, Justin, additional, Baujat, Bertrand, additional, Fakhry, Nicolas, additional, Albert, S., additional, Andry, G., additional, Babin, E., additional, Bach, C., additional, Badet, J.-M., additional, Badoual, C., additional, Baglin, A.C., additional, Banal, A., additional, Barry, B., additional, Baudin, E., additional, Baujat, B., additional, Bensadoun, R.J., additional, Bertolus, C., additional, Bessède, J.-P., additional, Blanchard, D., additional, Borel, C., additional, Bozorg-Grayeli, A., additional, Breheret, R., additional, Breton, P., additional, Brugel, L., additional, Calais, G., additional, Casiraghi, O., additional, Cassagnau, E., additional, Castillo, L., additional, Ceruse, P., additional, Chabolle, F., additional, Chevalier, D., additional, Chobaut, J.C., additional, Choussy, O., additional, Cosmidis, A., additional, Coste, A., additional, Costes, V., additional, Crampette, L., additional, Darrouzet, V., additional, Demez, P., additional, Dessi, P., additional, Devauchelle, B., additional, Dolivet, G., additional, Dubrulle, F., additional, Duflo, S., additional, Dufour, X., additional, Faivre, S., additional, Fakhry, N., additional, Ferron, C., additional, Floret, F., additional, de Gabory, L., additional, Garrel, R., additional, Geoffrois, L., additional, Gilain, L., additional, Giovanni, A., additional, Girod, A., additional, Guerrier, B., additional, Hans, S., additional, Herman, P., additional, Hofman, P., additional, Housset, M., additional, Jankowski, R., additional, Jegoux, F., additional, Juliéron, M., additional, Kaminsky, M.-C., additional, Kolb, F., additional, St Guily, J. Lacau, additional, Laccoureye, L., additional, Lallemant, B., additional, Lang, P., additional, Lartigau, E., additional, Lavieille, J.-P., additional, Lefevre, M., additional, Leroy, X., additional, Malard, O., additional, Massip, F., additional, Mauvais, O., additional, Merol, J.-C., additional, Michel, J., additional, Mom, T., additional, Morinière, S., additional, de Monès, E., additional, Moulin, G., additional, Noel, G., additional, Poissonnet, G., additional, Prades, J.-M., additional, Radulesco, T., additional, de Raucourt, D., additional, Reyt, E., additional, Righini, C., additional, Robin, Y. Marie, additional, Rolland, F., additional, Ruhin, B., additional, Sarroul, N., additional, Schultz, P., additional, Serrano, E., additional, Sterkers, O., additional, Strunski, V., additional, Sudaka, A., additional, Tassart, M., additional, Testelin, S., additional, Thariat, J., additional, Timochenko, A., additional, Toussaint, B., additional, Coste, E. Uro, additional, Valette, G., additional, Van den Abbeele, T., additional, Varoquaux, A., additional, Veillon, F., additional, Vergez, S., additional, and Wassef, M., additional

Published
2021
Full Text
View/download PDF

32. Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC) : depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms

Author

Grünwald, Viktor, Powles, T., Kopyltsov, E., Kozlov, V., Alonso Gordoa, T., Eto, M., Hutson, T., Motzer, R., Winquist, E., Maroto, P., Keam, B., Procopio, G., Wong, S., Melichar, B., Rolland, F., Oya, M., Rodriguez-Lopez, K., Saito, K., Smith, A., and Porta, C.

Subjects
Medizin
Published
2021

33. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Author

Motzer, R, Alekseev, B, Rha, SY, Porta, C, Eto, M, Powles, T, Grunwald, V, Hutson, TE, Kopyltsov, E, Mendez-Vidal, MJ, Kozlov, V, Alyasova, A, Hong, SH, Kapoor, A, Gordoa, TA, Merchan, JR, Winquist, E, Maroto, P, Goh, JC, Kim, M, Gurney, H, Patel, V, Peer, A, Procopio, G, Takagi, T, Melichar, B, Rolland, F, De Giorgi, U, Wong, S, Bedke, J, Schmidinger, M, Dutcus, CE, Smith, AD, Dutta, L, Mody, K, Perini, RF, Xing, DY, Choueiri, TK, and CLEAR Trial Investigators

Subjects
Oncology, Male, Programmed Cell Death 1 Receptor, Medizin, Pembrolizumab, 030204 cardiovascular system & hematology, urologic and male genital diseases, chemistry.chemical_compound, 0302 clinical medicine, Renal cell carcinoma, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Sunitinib, Medicine, 030212 general & internal medicine, Humanized, Aged, 80 and over, General Medicine, Middle Aged, female genital diseases and pregnancy complications, Kidney Neoplasms, Progression-Free Survival, Quinolines, Female, Lenvatinib, medicine.drug, Adult, medicine.medical_specialty, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Antibodies, 03 medical and health sciences, Internal medicine, Carcinoma, Humans, Progression-free survival, Everolimus, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged, business.industry, Phenylurea Compounds, Renal Cell, medicine.disease, Survival Analysis, chemistry, business
Abstract

Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced renal cell carcinoma and no previous systemic therapy to receive lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously once every 3 weeks), lenvatinib (18 mg orally once daily) plus everolimus (5 mg orally once daily), or sunitinib (50 mg orally once daily, alternating 4 weeks receiving treatment and 2 weeks without treatment). The primary end point was progression-free survival, as assessed by an independent review committee in accordance with Response Evaluation Criteria in Solid Tumors, version 1.1. Overall survival and safety were also evaluated.A total of 1069 patients were randomly assigned to receive lenvatinib plus pembrolizumab (355 patients), lenvatinib plus everolimus (357), or sunitinib (357). Progression-free survival was longer with lenvatinib plus pembrolizumab than with sunitinib (median, 23.9 vs. 9.2 months; hazard ratio for disease progression or death, 0.39; 95% confidence interval [CI], 0.32 to 0.49; P0.001) and was longer with lenvatinib plus everolimus than with sunitinib (median, 14.7 vs. 9.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.80; P0.001). Overall survival was longer with lenvatinib plus pembrolizumab than with sunitinib (hazard ratio for death, 0.66; 95% CI, 0.49 to 0.88; P = 0.005) but was not longer with lenvatinib plus everolimus than with sunitinib (hazard ratio, 1.15; 95% CI, 0.88 to 1.50; P = 0.30). Grade 3 or higher adverse events emerged or worsened during treatment in 82.4% of the patients who received lenvatinib plus pembrolizumab, 83.1% of those who received lenvatinib plus everolimus, and 71.8% of those who received sunitinib. Grade 3 or higher adverse events occurring in at least 10% of the patients in any group included hypertension, diarrhea, and elevated lipase levels.Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme; CLEAR ClinicalTrials.gov number, NCT02811861.).

Published
2021

34. 935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)

Author

Galot, R., Le Tourneau, C., Licitra, L.F.L., Even, C., Daste, A., Henry, S., Borel, C., Abdeddaim, C., Seront, E., Prevost, J.B., Rutten, A., Saada, E.B., Rolland, F., Livi, L., Specenier, P.M.C., Leys, J., Olungu, C., Fortpied Lefevre, C., Joaquim, A., and Machiels, J-P.

Published
2023
Full Text
View/download PDF

36. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Author

Grawis, G., Pignot, G., Flechon, A., Fendler, J.P., Chevreau, C., Soulie, M., Mahammedi, H., Guy, L., Laguerre, B., Verhoest, G., Guillot, A., Mottet, N., Joly, F., Doerfler, A., Abadie-Lacourtoisie, S., Azzouzi, A.R., Mongiat, P., Geoffrois, L., Eschwege, P., Di Fiore, F., Roubaud, G., Hoepffner, J.L., Barthelemy, P., Lang, H., Voog, E., Mandron, E., Tourani, J.M., Serrrate, C., Colau, A., Saldana, C., de La Taille, A., Nguyen, T., Kleinclauss, F., Loriot, Y., Irani, J., Eymard, J.C., Larre, S., Huillard, O., Zerbib, M., Rolland, F., Rigaud, J., Houede, N., Droupy, S., Malouf, G., Roupret, M., El Demery, M., Legon, C., Vieillot, S., Letang, N., Lharidon, T., Gaschignard, N., Hilgers, W., Davin, J.L., Pfister, Christian, Harter, Valentin, Allory, Yves, Radvanyi, François, and Culine, Stéphane

Published
2020
Full Text
View/download PDF

38. Re: Androgen-Deprivation Therapy Alone or with Docetaxel in Non-Castrate Metastatic Prostate Cancer (GETUG-AFU 15): A Randomised, Open-Label, Phase 3 Trial

Author

Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., Rolland, F., Théodore, C., Deplanque, G., Ferrero, J. M., Pouessel, D., Mourey, L., Beuzeboc, P., Zanetta, S., Habibian, M., Berdah, J. F., Dauba, J., Baciuchka, M., Platini, C., Linassier, C., Labourey, J. L., Machiels, J. P., El Kouri, C., Ravaud, A., Suc, E., Eymard, J. C., Hasbini, A., Bousquet, G., and Soulie, M.

Published
2013
Full Text
View/download PDF

39. GETUG collaborative group. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma : Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

Author

Negrier, S, Rioux-Leclercq, N, Ferlay, C, Gross-Goupil, M, Gravis, G, Geoffrois, L, Chevreau, C, Boyle, H, Rolland, F, Blanc, E, Ravaud, A, Dermeche, S, Flechon, A, Albiges, L, Pérol, D, Escudier, B, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2020

41. 63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies

Author

Le Tourneau, C., primary, Cassier, P., additional, Rolland, F., additional, Salas, S., additional, Limacher, J-M., additional, Capitain, O., additional, Lantz, O., additional, Lalanne, A., additional, Ekwegbara, C., additional, Tavernaro, A., additional, Makhloufi, H., additional, Bendjama, K., additional, and Delord, J-P., additional

Published
2020
Full Text
View/download PDF

42. 712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial

Author

Courcier, J., primary, Dalban, C., additional, Laguerre, B., additional, Ladoire, S., additional, Barthélémy, P., additional, Oudard, S., additional, Joly, F., additional, Gravis Mescam, G., additional, Chevreau, C.M., additional, Geoffrois, L., additional, Deluche, E., additional, Rolland, F., additional, Topart, D., additional, Culine, S., additional, Négrier, S., additional, Mahammedi, H., additional, Tantot, F., additional, Escudier, B., additional, Flippot, R., additional, and Albiges, L., additional

Published
2020
Full Text
View/download PDF

43. 735P Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study

Author

Guillaume, Z., primary, Colomba-Blameble, E., additional, Barthélémy, P., additional, Saldana, C., additional, Dumont, C., additional, Laguerre, B., additional, Maillet, D., additional, Vicier, C., additional, Rolland, F., additional, Borchiellini, D., additional, Thouvenin, J., additional, Albiges, L., additional, Auclin, E., additional, Oudard, S., additional, and Thibault, C., additional

Published
2020
Full Text
View/download PDF

44. 724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)

Author

Thibault, C., primary, Elaidi, R.T., additional, Fléchon, A., additional, Albiges, L., additional, Joly, C., additional, Barthélémy, P., additional, Gross Goupil, M., additional, Chevreau, C.M., additional, Joly, F., additional, Rolland, F., additional, Laguerre, B., additional, Gravis, G., additional, Brihoum, M., additional, Timsit, M-O., additional, Pecuchet, N., additional, Allory, Y., additional, and Oudard, S., additional

Published
2020
Full Text
View/download PDF

45. 526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

Author

Rousseau, B.J-C., primary, Bieche, I., additional, Pasmant, E., additional, Simmet, V., additional, Hamzaoui, N., additional, Masliah-Planchon, J., additional, Pouessel, D., additional, Bruyas, A., additional, Augereau, P., additional, Grob, J-J., additional, Rolland, F., additional, Saada-Bouzid, E., additional, Cohen, R., additional, Bouche, O., additional, Hoog-Labouret, N., additional, Legrand, F., additional, Simon, C., additional, Lamrani-Ghaouti, A., additional, Chevret, S., additional, and Marabelle, A., additional

Published
2020
Full Text
View/download PDF

46. LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck

Author

Bourhis, J., primary, Sun, X., additional, Le Tourneau, C., additional, Pointreau, Y., additional, Sire, C., additional, Kaminsky-Forrett, M-C., additional, Coutte, A., additional, Alfonsi, M., additional, Boisselier, P., additional, Martin, L., additional, Delord, J-P., additional, Clatot, F., additional, Biau, J., additional, Rolland, F., additional, Gollmer, K., additional, Szyldergemajn, S.A., additional, Even, C., additional, and Tao, Y., additional

Published
2020
Full Text
View/download PDF

47. 720P Randomised phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Interim analysis (IA) of SURF study

Author

Thiery-Vuillemin, A., primary, Gravis, G., additional, Constans Schlurmann, F., additional, Bompas, E., additional, Rolland, F., additional, Gross-Goupil, M., additional, Vano, Y.A., additional, Guillot, A., additional, Barthélémy, P., additional, Joly, C., additional, Laramas, M., additional, Dourthe, L.M., additional, Maurina, T., additional, Gauthier Petithuguenin, H., additional, Taillandy, K., additional, Meurisse, A., additional, Vernerey, D., additional, and Albiges, L., additional

Published
2020
Full Text
View/download PDF

48. Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Author

Pfister, Christian, primary, Harter, Valentin, additional, Allory, Yves, additional, Radvanyi, François, additional, Culine, Stéphane, additional, Grawis, G., additional, Pignot, G., additional, Flechon, A., additional, Fendler, J.P., additional, Chevreau, C., additional, Soulie, M., additional, Mahammedi, H., additional, Guy, L., additional, Laguerre, B., additional, Verhoest, G., additional, Guillot, A., additional, Mottet, N., additional, Joly, F., additional, Doerfler, A., additional, Abadie-Lacourtoisie, S., additional, Azzouzi, A.R., additional, Mongiat, P., additional, Geoffrois, L., additional, Eschwege, P., additional, Di Fiore, F., additional, Roubaud, G., additional, Hoepffner, J.L., additional, Barthelemy, P., additional, Lang, H., additional, Voog, E., additional, Mandron, E., additional, Tourani, J.M., additional, Serrrate, C., additional, Colau, A., additional, Saldana, C., additional, de La Taille, A., additional, Nguyen, T., additional, Kleinclauss, F., additional, Loriot, Y., additional, Irani, J., additional, Eymard, J.C., additional, Larre, S., additional, Huillard, O., additional, Zerbib, M., additional, Rolland, F., additional, Rigaud, J., additional, Houede, N., additional, Droupy, S., additional, Malouf, G., additional, Roupret, M., additional, El Demery, M., additional, Legon, C., additional, Vieillot, S., additional, Letang, N., additional, Lharidon, T., additional, Gaschignard, N., additional, Hilgers, W., additional, and Davin, J.L., additional

Published
2020
Full Text
View/download PDF

49. Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France

Author

Moya-Plana, A., primary, Aupérin, A., additional, Obongo, R., additional, Baglin, A., additional, Ferrand, F.R., additional, Baujat, B., additional, Saroul, N., additional, Casiraghi, O., additional, Vergez, S., additional, Herman, P., additional, Janot, F., additional, Thariat, J., additional, Vérillaud, B., additional, de Gabory, L., additional, Albert, S., additional, Andry, G., additional, Babin, E., additional, Bach, C., additional, Badet, J.-M., additional, Badoual, C., additional, Baglin, A.C., additional, Banal, A., additional, Barry, B., additional, Baudin, E., additional, Bensadoun, R.J., additional, Bertolus, C., additional, Bessède, J.-P., additional, Blanchard, D., additional, Borel, C., additional, Bozorg-Grayeli, A., additional, Breheret, R., additional, Breton, P., additional, Brugel, L., additional, Calais, G., additional, Cassagnau, E., additional, Castillo, L., additional, Ceruse, P., additional, Chabolle, F., additional, Chevalier, D., additional, Chobaut, J.C., additional, Choussy, O., additional, Cosmidis, A., additional, Coste, A., additional, Costes, V., additional, Crampette, L., additional, Darrouzet, V., additional, Demez, P., additional, Dessi, P., additional, Devauchelle, B., additional, Digue, L., additional, Dolivet, G., additional, Dubrulle, F., additional, Duflo, S., additional, Dufour, X., additional, Even, C., additional, Faivre, S., additional, Fakhry, N., additional, Ferron, C., additional, Floret, F., additional, Garrel, R., additional, Geoffrois, L., additional, Gilain, L., additional, Giovanni, A., additional, Girod, A., additional, Guerrier, B., additional, Hans, S., additional, Hofman, P., additional, Housset, M., additional, Jankowski, R., additional, Jegoux, F., additional, Juliéron, M., additional, Kaminsky, M.-C., additional, Kolb, F., additional, Lacau St Guily, J., additional, Laccoureye, L., additional, Lallemant, B., additional, Lang, P., additional, Lartigau, E., additional, Lavieille, J.-P., additional, Lefevre, M., additional, Leroy, X., additional, Malard, O., additional, Massip, F., additional, Mauvais, O., additional, Merol, J.-C., additional, Michel, J., additional, Mom, T., additional, Morinière, S., additional, de Monès, E., additional, Moulin, G., additional, Moya-Plana, A., additional, Noel, G., additional, Poissonnet, G., additional, Prades, J.-M., additional, de Raucourt, D., additional, Reyt, E., additional, Righini, C., additional, Marie Robin, Y., additional, Rolland, F., additional, Ruhin, B., additional, Sarroul, N., additional, Schultz, P., additional, Serrano, E., additional, Sterkers, O., additional, Strunski, V., additional, Sudaka, A., additional, Tassart, M., additional, Testelin, S., additional, Timochenko, A., additional, Toussaint, B., additional, Uro Coste, E., additional, Valette, G., additional, Van den Abbeele, T., additional, Varoquaux, A., additional, Veillon, F., additional, and Wassef, M., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results